Private health insurance and the Pharmaceutical Benefits Scheme: how effective has recent government policy been?

Aust Health Rev

Centre for Health Economics, Monash University, PO Box 477, West Heidelberg, Vic 3081.

Published: April 2016

The cost to government of the Pharmaceutical Benefits Scheme (PBS) is rising at over 10 percent per annum. The government subsidy to Private Health Insurance (PHI) is about $2.4 billion and rising. Despite this, the queues facing public patients - which were the primary justification for the assistance to PHI - do not appear to be shortening. Against this backdrop, we seek to evaluate recent policies. It is shown that the reason commonly given for the support of PHI - the need to preserve the market share of private hospitals and relieve pressure upon public hospitals - is based upon a factually incorrect analysis of the hospital sector in the last decade. It is similarly true that the 'problem' of rising pharmaceutical expenditures has been exaggerated. The common element in both sets of policies is that they result in cost shifting from the public to the private purse and have little to do with the quality or quantity of health services.

Download full-text PDF

Source
http://dx.doi.org/10.1071/ah040034DOI Listing

Publication Analysis

Top Keywords

private health
8
health insurance
8
pharmaceutical benefits
8
benefits scheme
8
private
4
insurance pharmaceutical
4
scheme effective
4
effective government
4
government policy
4
policy been?
4

Similar Publications

Background: Cabotegravir + rilpivirine (CAB + RPV) administered via intramuscular gluteal injections is the first complete long-acting regimen for maintaining human immunodeficiency virus type 1 (HIV-1) virologic suppression. We present substudy results on short-term repeat intramuscular CAB + RPV long-acting thigh injections in participants with ≥3 years of experience with gluteal administration during the ATLAS-2M study.

Methods: Substudy phases included screening, thigh injection (day 1-week 16), and return to gluteal injection (week 16-week 24).

View Article and Find Full Text PDF

Reimbursement policies of Swiss health insurances for the surgical treatment of symptomatic breast hypertrophy: a retrospective cohort study.

Swiss Med Wkly

January 2025

Department of Plastic, Reconstructive and Aesthetic Surgery, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.

Background: Patients with symptomatic breast hypertrophy typically suffer from chronic back pain, recurrent skin irritation at the inframammary fold and/or low self-esteem resulting in impaired quality of life. Reduction mammaplasty has been shown to effectively treat symptomatic breast hypertrophy with high patient satisfaction. Despite the obvious benefits, reimbursement requests for reduction mammaplasty are initially often refused by the patient's health insurance company, thereby frequently resulting in additional examinations and eventually extra expenses.

View Article and Find Full Text PDF

Objectives: To assess the contemporary malignancy rate in isolated de novo red patches in the bladder and associated risk factors for better selection of red patch biopsy.

Patients: Patients from the IDENTIFY dataset; Patients referred to secondary care with suspected urinary tract cancer and found to have isolated de novo red patches on cystoscopy.

Methods: We reported the unadjusted cancer prevalence in isolated de novo red patches that were biopsied; multivariable logistic regression was used to explore cancer-associated risk factors including age, sex, smoking, type of haematuria, LUTS, UTIs and a suspicious-looking red patch (as reported by the cystoscopist).

View Article and Find Full Text PDF

Objectives: To explore the challenges and opportunities for research capacity development in the sports chiropractic field.

Methods: A qualitative description study was conducted using semi-structured interviews with 20 sports chiropractic researchers from eight countries and focus group interviews with 12 sports chiropractic leaders from Canada.

Results: Challenges and opportunities for research capacity development were identified within four main themes - 1) affiliations and collaborations, 2) human resources, 3) financial resources, and 4) operational resources.

View Article and Find Full Text PDF

Assessing response to stressful emotions: a controlled crossover study using pupillometry.

Porto Biomed J

January 2025

Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.

Background: Fear and horror induce autonomic protective responses, acting as "survival intelligence." Pupillometry is an innovative method that captures real-time autonomic nervous system reactions to stress.

Objective: To evaluate the feasibility of pupillometry to assess the acute response to a passive real-life stressor-viewing a truthful war scene.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!